Information Provided By: 
Fly News Breaks for December 9, 2016
AZN
Dec 9, 2016 | 07:38 EDT
As previously reported, Leerink analyst Seamus Fernandez upgraded AstraZeneca to Outperform from Market Perform, with a $34 price target, saying the recent weakness in shares provides an "excellent entry point" ahead of several critical pipeline events that have the potential "to transform this giant into an exciting growth story." The analyst says AstraZeneca is now his top pick for 2017.
News For AZN From the Last 2 Days
AZN
Apr 25, 2024 | 05:52 EDT
Consensus $4.56. Backs FY24 revenue view up low double-digit to low teens percentage, consensus $50.95B. Sees FY24 core tax rate 18%-22%.
